US › Healthcare

Tilray Inc (TLRY)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$3.94+0.25%

Last close · 2026-09-17

Latest quarter · ended 2026-05-31

Revenue

$281.7M

Revenue YoY

-8.6%

Net profit

$-49.6M

EPS

$-0.43

EPS estimate

$-0.02

Net margin

-17.6%

EPS came in at -0.43 against a street estimate of -0.02 — a miss of 2050.0%.

Key statistics

Market cap

$560.3M

Forward P/E

1,000.0

P/B

0.35

Book value

$3.02

EPS (TTM)

$-1.06

52-week high

$23.20

52-week low

$3.67

50-day MA

$4.42

200-day MA

$6.50

Beta

1.92

Analyst view

Analysts rate Tilray Inc a buy (4 buy, 8 hold, 0 sell out of 12) with an average price target of $7.84.

Shareholding

Insiders

1.67%

Institutions

10.91%

Largest institutional holders

Fund	Stake
1 NORTH WEALTH SERVICES LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tilray Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.